KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Average (2016 - 2025)

Jazz Pharmaceuticals has reported Equity Average over the past 15 years, most recently at $4.1 billion for Q4 2025.

  • Quarterly Equity Average changed 0.15% to $4.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 billion through Dec 2025, changed 0.15% year-over-year, with the annual reading at $4.2 billion for FY2025, 7.43% up from the prior year.
  • Equity Average was $4.1 billion for Q4 2025 at Jazz Pharmaceuticals, up from $3.8 billion in the prior quarter.
  • Over five years, Equity Average peaked at $4.1 billion in Q4 2025 and troughed at $2.9 billion in Q4 2022.
  • The 5-year median for Equity Average is $3.8 billion (2022), against an average of $3.7 billion.
  • Biggest five-year swings in Equity Average: surged 33.26% in 2021 and later decreased 26.32% in 2022.
  • Tracing JAZZ's Equity Average over 5 years: stood at $4.0 billion in 2021, then fell by 26.23% to $2.9 billion in 2022, then increased by 23.93% to $3.6 billion in 2023, then rose by 14.37% to $4.1 billion in 2024, then grew by 0.15% to $4.1 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $4.1 billion, $3.8 billion, and $3.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.